TR200101704T2 - Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı - Google Patents
Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımıInfo
- Publication number
- TR200101704T2 TR200101704T2 TR2001/01704T TR200101704T TR200101704T2 TR 200101704 T2 TR200101704 T2 TR 200101704T2 TR 2001/01704 T TR2001/01704 T TR 2001/01704T TR 200101704 T TR200101704 T TR 200101704T TR 200101704 T2 TR200101704 T2 TR 200101704T2
- Authority
- TR
- Turkey
- Prior art keywords
- mek inhibitor
- transplant rejection
- prevent transplant
- prevent
- rejection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11236998P | 1998-12-15 | 1998-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200101704T2 true TR200101704T2 (tr) | 2001-11-21 |
Family
ID=22343544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/01704T TR200101704T2 (tr) | 1998-12-15 | 1999-12-14 | Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1140046A1 (ko) |
| JP (1) | JP2002532414A (ko) |
| KR (1) | KR20010101203A (ko) |
| AU (1) | AU2180500A (ko) |
| CA (1) | CA2346684A1 (ko) |
| HU (1) | HUP0104607A3 (ko) |
| IL (1) | IL143231A0 (ko) |
| TR (1) | TR200101704T2 (ko) |
| WO (1) | WO2000035435A1 (ko) |
| ZA (1) | ZA200103765B (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4－碘苯氨基苯氧肟酸的氧合酯 |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| AU2004283148A1 (en) | 2003-10-21 | 2005-05-06 | Warner-Lambert Company Llc | Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| EA025871B9 (ru) | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| PE20080371A1 (es) | 2006-05-19 | 2008-04-09 | Wyeth Corp | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| US8993630B2 (en) | 2008-11-10 | 2015-03-31 | Bayer Intellectual Property Gmbh | Substituted sulphonamido phenoxybenzamides |
| WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| CN102574782B (zh) | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| CA2816188A1 (en) | 2010-10-29 | 2012-05-03 | Marion Hitchcock | Substituted phenoxypyridines |
| CR20200237A (es) | 2012-10-12 | 2020-07-26 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245) |
| IL278194B2 (en) | 2018-04-24 | 2023-12-01 | Translational Drug Dev Llc | Amide compounds as kinase inhibitors, compositions and methods of treatment |
| WO2020142745A1 (en) * | 2019-01-04 | 2020-07-09 | Translational Drug Development, Llc | Methods of treating graft versus host disease and neoplastic disease with amide compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155110A (en) * | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| WO1996031206A2 (en) * | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
| US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| ES2229515T3 (es) * | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| WO1999034792A1 (en) * | 1998-01-06 | 1999-07-15 | The General Hospital Corporation | Use of mek1 inhibitors as protective agents against damage due to ischemia |
-
1999
- 1999-12-14 IL IL14323199A patent/IL143231A0/xx unknown
- 1999-12-14 HU HU0104607A patent/HUP0104607A3/hu unknown
- 1999-12-14 WO PCT/US1999/029591 patent/WO2000035435A1/en not_active Application Discontinuation
- 1999-12-14 AU AU21805/00A patent/AU2180500A/en not_active Abandoned
- 1999-12-14 JP JP2000587756A patent/JP2002532414A/ja active Pending
- 1999-12-14 EP EP99966203A patent/EP1140046A1/en not_active Withdrawn
- 1999-12-14 TR TR2001/01704T patent/TR200101704T2/xx unknown
- 1999-12-14 CA CA002346684A patent/CA2346684A1/en not_active Abandoned
- 1999-12-14 KR KR1020017007397A patent/KR20010101203A/ko not_active Application Discontinuation
-
2001
- 2001-05-09 ZA ZA200103765A patent/ZA200103765B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0104607A3 (en) | 2002-12-28 |
| WO2000035435A1 (en) | 2000-06-22 |
| CA2346684A1 (en) | 2000-06-22 |
| KR20010101203A (ko) | 2001-11-14 |
| AU2180500A (en) | 2000-07-03 |
| EP1140046A1 (en) | 2001-10-10 |
| IL143231A0 (en) | 2002-04-21 |
| ZA200103765B (en) | 2002-05-09 |
| HUP0104607A2 (hu) | 2002-04-29 |
| JP2002532414A (ja) | 2002-10-02 |
| WO2000035435A9 (en) | 2001-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200101704T2 (tr) | Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı | |
| TR199901191T2 (xx) | Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�. | |
| TR199900310T2 (xx) | Trombin inhibit�rleri | |
| ATE353641T1 (de) | Benzamide als kaliumkanal-inhibitoren | |
| ES2173948T3 (es) | Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. | |
| TR200200160T2 (tr) | Antiinflamatuar ajanlar olarak imidazoller ve triazoller | |
| MY142948A (en) | Benzophenones as inhibitors of reverse transcriptase | |
| TR200100805T2 (tr) | Tetrahidropiridoeterler | |
| WO2004046308A3 (en) | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state | |
| DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
| TR200003170T2 (tr) | MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar | |
| ID22042A (id) | Benzonaftiridin sebagai pengobatan cabang tenggorokan | |
| ATE273690T1 (de) | Zusammensetzung zur hautdesinfizierung | |
| TR200200359T2 (tr) | Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması | |
| NO2019032I1 (no) | Treosulfan | |
| SE9802937D0 (sv) | Novel compounds | |
| TR199900505T2 (ko) | ||
| BR9912307A (pt) | Inibidores fkbp | |
| FR2872431B1 (fr) | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire | |
| UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada | |
| SE0000307D0 (sv) | Method and formulation för treatment of vasoconstriction | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| NO995849L (no) | Aldehydfritt desinfeksjonsmiddel for overflater og instrumenter | |
| TR199802496T2 (xx) | Konjestif kalp yetmezli�ini tedavi i�in form�lasyon. | |
| IL147223A0 (en) | The use of the protein uk 114 for inhibiting organ transplant rejection |